Cartesian Therapeutics, Inc. (RNAC) company profile
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
About Cartesian Therapeutics
Pharmaceutical Preparations, SIC 2834
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that develops mRNA-engineered cell therapies for the treatment of autoimmune diseases. The company uses a proprietary platform to insert messenger RNA into cells, enabling outpatient administration without the need for pre-treatment chemotherapy or viral integration. Its lead product candidate is Descartes-08, an autologous chimeric antigen receptor T-cell therapy in clinical evaluation for conditions such as generalized myasthenia gravis and myositis. The company also developed Descartes-15 for multiple myeloma and explores in-vivo cell engineering technologies. Its primary target patients are individuals living with serious, chronic autoimmune disorders.
The company is headquartered in Frederick, Maryland, where it operates an internal, current good manufacturing practice compliant facility for research, development, and clinical cell therapy production. Cartesian conducts clinical trials across multiple patient cohorts in the United States. Its intellectual property portfolio includes issued and pending patents across various global jurisdictions, including the United States, Canada, Israel, Japan, and South Korea.
Summary of the business section of Cartesian Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cartesian Therapeutics, Inc.
- Founded
- 2007
- Headquarters
- Frederick, MD
- Address
- 7495 New Horizon Way 21703
- Phone
- (301) 348-8698
- Website
- www.selectabio.com
- Employees
- 75, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- RNAC
- Former tickers
- SELB until Nov 27, 2023
- Exchange
- Nasdaq
- IPO date
- Jun 23, 2016
- Shares outstanding
- 30M, Jul 31, 2026
- Public float
- $108.74M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Apr 5, 2024
- SEC CIK
- 1453687
- CUSIP
- 816212104
- ISIN
- US8162121045
- FIGI
- BBG001J19Q25
- Share class FIGI
- BBG001V0FQQ0
- LEI
- 529900NMN0LACZOL7C43
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carsten Brunn | President and CEO, Director | 323,530 |
| Milos Miljkovic | Chief Medical Officer | 58,820 |
| Blaine Davis | Chief Financial Officer | 121,220 |
| Emily English | Chief Operations Officer | 94,226 |
| June Ann Seymour | Chief Accounting Officer | 6,500 |
| Christopher M. Jewell | Chief Scientific Officer | 62,490 |
| Metin Kurtoglu | Chief Technology Officer | 62,258 |
| Michael Singer | Director | 544,381 |
| Timothy C. Barabe | Director | 56,966 |
| Patrick J. Zenner | Director | 12,974 |
| Nishan M. DeSilva | Director | 11,366 |
| Timothy A. Springer | Director | 9,633,493 |
| Kemal Malik | Director | 11,133 |
| Adrian Ion Bot | Director | 5,800 |
| Carrie Smith Cox | Director | 15,629 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.33M | -$633.79K | $2.02M | $25 | – |
| FY2024 | $7.31M | $6.54M | $2.79M | $61 | – |
| FY2023 | $6.11M | $6.38M | $1.82M | $70 | – |
| FY2022 | $4.29M | -$588.62K | $1.66M | $35 | – |
| FY2021 | $3.67M | $4.28M | $1.34M | $108 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Carsten Brunn President and Chief Executive Officer | $674.00K | $973.48K | $2.31M | $363.96K | $4.11K | $4.33M | -41% |
| Blaine Davis Chief Financial Officer | $475.86K | $372.46K | $884.12K | $205.57K | $11.91K | $1.95M | -51% |
| Milos Miljkovic Chief Medical Officer | $439.00K | $321.67K | $766.42K | $118.53K | $11.91K | $1.66M | +23% |
| Christopher Jewell Former Chief Scientific Officer | $390.67K | $375.05K | $661.81K | $144.20K | $443.98K | $2.02M | +19% |
| Metin Kurtoglu Former Chief Technology Officer | $163.49K | $775.93K | $984.44K | $60.43K | $489.74K | $2.47M | -9% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 23, 2016
- Offer price
- $14.00
- Securities offered
- 5,000,000
- Gross proceeds
- $70.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Dec 20, 2016
“The initial public offering price per share is $14.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 75 full-time employees, 62 of whom are primarily engaged in research and development activities and 13 of whom are primarily engaged in corporate functions.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 19, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 13, 2023 | Name change | Name changed from SELECTA BIOSCIENCES INC to Cartesian Therapeutics, Inc. |
| Nov 13, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 14, 2023 | Late filing | Notification of late filing |
| Jun 3, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 23, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 8, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?